Redhill Biopharma Ltd
NASDAQ:RDHL

Watchlist Manager
Redhill Biopharma Ltd Logo
Redhill Biopharma Ltd
NASDAQ:RDHL
Watchlist
Price: 1.18 USD 2.61% Market Closed
Market Cap: 3.9m USD

Operating Margin
Redhill Biopharma Ltd

-156.7%
Current
-34%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-156.7%
=
Operating Profit
-19m
/
Revenue
12.1m

Operating Margin Across Competitors

No Stocks Found

Redhill Biopharma Ltd
Glance View

Market Cap
3.9m USD
Industry
Pharmaceuticals

RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. The firm promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.

RDHL Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-156.7%
=
Operating Profit
-19m
/
Revenue
12.1m
What is the Operating Margin of Redhill Biopharma Ltd?

Based on Redhill Biopharma Ltd's most recent financial statements, the company has Operating Margin of -156.7%.

Back to Top